Biotechnology company Emergent BioSolutions Inc. said Friday U.S. health regulators approved a new version of its anthrax vaccine that requires fewer injections. The latest formulation of Biothrax approved by the Food and Drug Administration requires five doses, compared with six injections for the previous version.
